All enrolled individuals who acquired at the very least a person dose of zosuquidar or placebo for the duration of induction were being monitored for your prevalence of adverse activities (439 clients, 219 on zosuquidar and 210 on placebo). The most typical adverse gatherings were being associated with the period of prolonged and significant myelos